Targets in osteoporosis treatment;Metas para o tratamento da osteoporose

Arquivos Brasileiros de Endocrinologia e Metabologia

Volumn 58, Issue 5, 2014, Pages 409-410

  Bandeira, Francisco ^a   de Paula, Francisco J A ^b   Lazaretti Castro, Marise ^c   Premaor, Melissa Orlandin ^d  

^a MINISTÉRIO DA SAÚDE   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^d FEDERAL UNIVERSITY OF SANTA MARIA   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT;

BONE DENSITY; DRUG EFFECTS; EXPERIMENTAL THERAPY; HUMAN; OSTEOPOROSIS; TRENDS;

BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; HUMANS; OSTEOPOROSIS; THERAPIES, INVESTIGATIONAL;

EID: 84906667937     PISSN: 00042730     EISSN: 16779487     Source Type: Journal    
DOI: 10.1590/0004-2730000003363     Document Type: Editorial

References (18)

1. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35(6):1364-1379.
2. Tamez-Pérez HE, Proskauer-Peña SL, Hernŕndez-Coria MI, Gar-ber AJ. AACE Comprehensive Diabetes Management Algorithm 2013. Endocr Pract. 2013;19(4):736-737.
3. Stone N, Robinson J, Lichtenstein A, et al. 2013 ACC/AHA Guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. Circulation. 2013; circ.0000437738.63853.7a.citation.
4. Jellinger PS, Smith DA, Mehta AE, Ganda O, Handelsman Y, Rod-bard HW, et al. American Association of Clinical Endocrinologists' Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis. Endocr Pract. 2012;18 Suppl 1:1-78.
5. Berglund L, Brunzell JD, Goldberg AC, Goldberg IJ, Sacks F, Mu-rad MH, et al. Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2012;97(9):2969-2989.
6. Weber MA, Schiffrin EL, White WB, Mann S, Lindholm LH, Kener-son JG, et al. Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. J Clin Hypertens (Greenwich). 2014;16(1):14-26.
7. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmel-farb C, Handler J, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311(5):507-520.
8. McCloskey E, Leslie WD. Goal-directed therapy in osteoporosis. J Bone Miner Res. 2013;28(3):439-441.
9. Sousa IO, Diniz E T, Marques T F, Griz L, Coutinho Mde A, Bandeira F. Short-term bone marker responses to teriparatide and strontium ranelate in patients with osteoporosis previously treated with bisphosphonates. Arq Bras Endocrinol Metabol. 2010;54(2):244-249.
10. Middleton ET, Steel SA, Aye M, Doherty SM. The effect of prior bisphosphonate therapy on the subsequent therapeutic effects of strontium ranelate over 2 years. Osteoporos Int. 2012;23(1):295-303.
11. Sebba AI. Significance of a decline in bone mineral density while receiving oral bisphosphonate treatment. Clin Ther. 2008;30(3):443-452.
12. Shane E, Burr D, Abrahamsen B, Adler RA, Brown TD, Cheung AM, et al. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the american society for bone and mineral research. J Bone Miner Res. 2014;29(1):1-23.
13. Carvalho NN, Voss LA, Almeida MO, Salgado CL, Bandeira F. Atypical femoral fractures during prolonged use of bisphosphona-tes: short-term responses to strontium ranelate and teriparatide. J Clin Endocrinol Metab. 2011;96(9):2675-2680.
14. Aspenberg P. Denosumab and atypical femoral fractures. Acta Or-thop. 2014; [Epub ahead of print].
15. Whitaker M, Guo J, Kehoe T, Benson G. Bisphosphonates for osteoporosis--where do we go from here? N Engl J Med. 2012;366(22):2048-2051.
16. Black DM, Bauer DC, Schwartz AV, Cummings SR, Rosen CJ. Continuing bisphosphonate treatment for osteoporosis--for whom and for how long? N Engl J Med. 2012;366(22):2051-2053.
17. Leslie WD, Aubry-Rozier B, Lamy O, Hans D; Manitoba Bone Density Program. TBS (trabecular bone score) and diabetes-related fracture risk. J Clin Endocrinol Metab. 2013;98(2):602-609.
18. Link TM. Osteoporosis imaging: state of the art and advanced imaging. Radiology. 2012;263(1):3-17.